Form 4 Oracle: Boston, MA -- Form4Oracle: Insider Trading Report: Keryx Biopharmaceuticals Inc (KERX)

Aug 27, 2008 (M2 PRESSWIRE via COMTEX) -- KERX | Quote | Chart | News | PowerRating -- As the stock was trading at less than 50 percent of its 52-week high, Weiss Michael S, Chief Executive Officer at Keryx Biopharmaceuticals Inc (KERX) has reported buying $60.50K today.This purchase has increased overall holdings of Weiss Michael S, Chief Executive Officer in Keryx Biopharmaceuticals Inc by 1000%.For a current, real-time summary of KERX insider activity, visit http://www.form4oracle.com/company?cik=0001114220&ticker=KERX

About Form4Oracle

Form4Oracle, LLC specializes in distributing insider trading information published by the SEC, making it accessible and actionable for all types of investors. To learn more about how tracking insider trading activity can improve your investment returns, visit http://www.form4oracle.com.

About Keryx Biopharmaceuticals Inc

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the acquisition, development, and commercialization of pharmaceutical products for the treatment of diabetes and cancer. Its endocrine/renal products include Sulonex, a Phase III and Phase IV clinical stage product for the treatment of diabetic nephropathy; and Zerenex, a Phase II clinical stage product for the treatment of hyperphosphatemia in patients with end-stage renal disease. The company's oncology products include KRX-0401, a Phase II clinical stage product for the treatment of renal cancer and other multiple forms of cancer; KRX-0402, a Phase II clinical stage product for the treatment of brain cancer; KRX-0601, a Phase II clinical stage product for the treatment of multiple forms of cancer; and KRX-0404, a pre-clinical stage product for the treatment of multiple forms of cancer. It also develops neurology products, including KRX-0701, a Phase II clinical stage product for the treatment of diabetic neuropathy; and KRX-0501, a Phase I clinical stage product for the treatment of neurological disorders. Keryx Biopharmaceuticals, Inc. has strategic alliances with Alfa Wassermann S.p.A.; Collaborative Study Group; Opocrin, S.p.A.; AEterna Zentaris, Inc.; The National Institutes of Health; Panion & BF Biotech, Inc.; Kyowa Hakko Kogyo Co., Ltd.; AusAm Biotechnologies, Inc.; Degussa AG; Japan Tobacco, Inc.; and Torii Pharmaceutical Co., Ltd. for the manufacture and commercialization of its products. The company was founded in 1998. It was formerly known as Paramount Pharmaceuticals, Inc. and changed its name to Lakaro Biopharmaceuticals, Inc. in 1999. Further, the company changed its name to Keryx Biopharmaceuticals, Inc. in 2000. Keryx Biopharmaceuticals, Inc. is based in New York, New York.

--------------------------------------------

The companies referenced in this report have not approved the statements made in this report. This report contains statements that imply risks and uncertainties. This material is for informational reporting purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Form4Oracle is not a licensed broker, broker dealer, market maker, investment banker, investment adviser, analyst or underwriter and is not compensated in this regard.

Please consult your broker to understand investing benefits and risks and prior to purchasing any securities mentioned herein.

CONTACT: Kimberly Sutton, on behalf of Form4Oracle Tel: +1 312 315 5077 e-mail: kimberly@form4oracle.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index